JasgitC(Chugh)SachdevMD

Oncology • Scottsdale, AZ

Director, Breast and GYN Early Trials

Join to view full profile

Dr. Sachdev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sachdev's full profile

Already have an account?

Office
10510 N 92nd ST
Suite 200
Scottsdale, AZ 85258
Phone+1 480-323-1350

Fax+1 480-323-1359
Is this information wrong?

Education & Training

University of TennesseeFellowship, Hematology and Medical Oncology, 2004 - 2007
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 2001 - 2004
Dayanand Medical College Class of 2000

Certifications & Licensure

AZ State Medical License 2010 - 2025
TN State Medical License 2007 - 2012
MS State Medical License 2007 - 2012
AR State Medical License 2008 - 2010

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. Start of enrollment: 2008 Oct 01
Unknown status
Phase 2
Temsirolimus as Second-line Therapy in HCC Start of enrollment: 2010 Feb 01
Unknown status
Phase 2
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors Start of enrollment: 2014 Oct 11
Terminated
Phase 1
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Start of enrollment: 2017 Oct 12
Active, not recruiting
Phase 1
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers Start of enrollment: 2021 Dec 31
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David R Spigel, Melissa...> ;Investigational New Drugs. 2023 Jun 1
4 citations
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton, Camille Gunderson Jackson, Kristopher LyBarger, Howard M Goodman, Linda R Duska, Haider...> ;Gynecologic Oncology. 2023 May 1
2 citations
Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Harshan Ravi, Andres M Arias-Lorza, James R Costello, Hyo Sook Han, Daniel K Jeong, Stephan G Klinz, Jasgit C Sachdev, Ronald L Korn, Natarajan Raghunand> ;Radiology. Imaging Cancer. 2023 Mar 1
6 citations
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, Erkut Borazanci, Manish R Sharma, Joseph M Custodio, Iulia Cristina Tudor, Hristina I Pashova, Stacie Peacock Sh...> ;Clinical Cancer Research. 2022 Aug 2
9 citations
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced can...
Timothy A Yap, Alberto Bessudo, Erika Hamilton, Jasgit Sachdev, Manish R Patel, Jordi Rodon, Lena Evilevitch, Meghan Duncan, Wei Guo, Sujatha Kumar, Sharon Lu, Bruce J...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
8 citations
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Amita Patnaik, Glen J. Weiss, Drew W. Rasco, Lisa Blaydorn, Amy Mirabella, Murali Beeram, Wei Guo, Sharon Lu, Hadi Danaee, Kristen McEachern, Ellie Im, Jasgit C. Sachdev> ;Cancer Chemotherapy and Pharmacology. 2021 Nov 8
31 citations
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R Moreau, Dawei...> ;Clinical Cancer Research. 2021 Aug 15
17 citations
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Phil...> ;Clinical Cancer Research. 2021 Jan 15
41 citations
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert Gray, Larr...> ;JAMA Oncology. 2021 Feb 1
19 citations
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Jasgit C. Sachdev, Pamela N. Munster, Donald W. Northfelt, Hyo S. Han, Cynthia X. Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Y. Moore, Arunthathi Thia...> ;Breast Cancer Research and Treatment. 2021 Feb 1
26 citations
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris ...> ;British Journal of Clinical Pharmacology. 2020 Sep 1
11 citations
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
Arkadiusz Z. Dudek, Li C Liu, James H. Fischer, Elizabeth L. Wiley, Jasgit C. Sachdev, Jonathan Bleeker, Randolph Hurley, Debra A. Tonetti, Gregory R. J. Thatcher, Rob...> ;Breast Cancer Research and Treatment. 2020 Jul 22
11 citations
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Charlotte Lemech, Natasha Woodward, Nancy Chan, Joanne E. Mortimer, Louie Naumovski, Silpa Nuthalapati, Bo Tong, Fang Jiang, Peter Ansell, Christine K. Ratajczak, Jasg...> ;Investigational New Drugs. 2020 Jun 10
403 citations
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
, , , , , , , , , , , , , , , , , , , , , > ;British Journal of Cancer. 2020 Apr 2
79 citations
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina Anne Piha-Paul, Jasgit C. Sachdev, Minal A. Barve, Patricia LoRusso, Russell Z. Szmulewitz, Sapna Pradyuman Patel, Primo N. Lara, Xiaotian Chen, Beibei Hu, Kevi...> ;Clinical Cancer Research. 2019 Nov 1
307 citations
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos, Steven E. Waggoner, Gregory A. Vidal, Monica M. Mita, John W. Moroney, Robert W. Holloway, Linda Van Le, Jasgit C. Sachdev, Eloise Cha...> ;JAMA Oncology. 2019 Aug 1
12 citations
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
Chia-Chi Lin, Hendrik Tobias Arkenau, Sharon Lu, Jasgit C. Sachdev, Javier de Castro Carpeño, Monica M. Mita, Rafal Dziadziuszko, Wu Chou Su, Dmitri Bobilev, Lorraine ...> ;British Journal of Cancer. 2019 Jul 16
16 citations
Update on Precision Medicine in Breast Cancer.
Jasgit C. Sachdev, Ana C. Sandoval, Mohammad Jahanzeb> ;Cancer Treatment and Research. 2019 Jan 1
222 citations
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Hope S. Rugo, Jean Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina Anne Piha-Paul, Philippe L. Bedard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Br...> ;Clinical Cancer Research. 2018 Jun 15
11 citations
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Theresa L. Werner, Jasgit C. Sachdev, Elizabeth M. Swisher, Martin Gutierrez, Muaiad Kittaneh, Mark N. Stein, Hao Xiong, Martin Dunbar, Danielle Sullivan, Philip Komar...> ;Cancer Medicine. 2018 Jun 1
147 citations
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Daniel D. Von Hoff, Monica M. Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald Parson...> ;Clinical Cancer Research. 2016 Feb 4
72 citations
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
Kyriakos P. Papadopoulos, Bassel F. El-Rayes, Anthony W. Tolcher, Amita Patnaik, Drew W. Rasco, R. D. Harvey, Patricia LoRusso, Jasgit C. Sachdev, Giovanni Abbadessa, ...> ;British Journal of Cancer. 2017 Oct 3
106 citations
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, Ronald G. Newbold, Gayle S. Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, J...> ;Clinical Cancer Research. 2017 Jul 15
558 citations
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Muhammad Shaalan Beg, Andrew Brenner, Jasgit C. Sachdev, Mitesh J. Borad, Yoon-Koo Kang, Jay Stoudemire, Susan Smith, Andreas G. Bader, Sinil Kim, David S. Hong> ;Investigational New Drugs. 2017 Apr 1
279 citations
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers
Johann S. de Bono, Ramesh K. Ramanathan, Lida Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David Smith, Joshua W....> ;Cancer Discovery. 2017 Feb 27
Join now to see all

Lectures

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Five Prime Therapeutics Presents Monotherapy Data from the Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at the 2019 ASCO Annual MeetingJune 1st, 2019
Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerNovember 23rd, 2016
Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian CancerOctober 25th, 2016
Join now to see all